VisionCare Ophthalmic Technologies News
News on VisionCare Ophthalmic Technologies (Ticker: JNJ) continually updated from thousands of sources around the net.
2 hrs ago | Seeking Alpha
Once again, Johnson & Johnson has come through for investors. The company just reported a very solid first-quarter earnings report.
Trending on the Topix Network
8 hrs ago | GuruFocus.com
FPA Crescent Fund's Steven Romick in the first quarter preferred to have cash ready to put to work in case volatility hit the markets, rather than buy new stocks.
The company as a whole may have reported strong first quarter results, but Johnson & Johnson has ended efforts to rival Allergan's popular Botox anti-wrinkle treatment.
Coca-Cola. The world's biggest beverage maker said Tuesday that the amount of soda it sold globally fell for first time in 15 years.
Johnson & Johnson was giving up some of Tuesday's gains , although analysts were largely upbeat about the company's better-than-expected first-quarter earnings report, as evidenced by a flurry of target price increases.
Several smartphone apps are available to help patients take their medications as prescribed.
's stock had its "underperform" rating reiterated by equities research analysts at Credit Suisse in a research note issued to investors on Wednesday, Analyst Ratings News reports.
Johnson & Johnson, the world's biggest maker of health-care products, beat expectations and raised its 2014 forecast by focusing on new drugs and reducing its reliance on medical devices.
Global equities were mixed with US markets continuing their recovery, while European and emerging markets struggled.
This Oct. 16 2012 photo shows Johnson and Johnson products, including Band Aid brand adhesive bandages, arranged for a photo in St. Petersburg, Fla.
Coca-Cola rose 4 percent after reporting higher sales of non-carbonated beverages.
U.S. stocks dipped on Tuesday, as gains in Coca Cola and Johnson & Johnson after their quarterly earnings were offset by mixed economic data and a resumed slide in momentum shares.
Johnson & Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view.
NEW YORK -- It's still early in first-quarter earnings season, but it looks like companies that beat analysts' earnings estimates and spike higher are going to have a hard time holding on to those gains.
The Scripps Research Institute has created a group to launch drug development companies based on the work of its scientists and its first collaborator is a big one: Johnson & Johnson Innovation.
Johnson & Johnson is set to report FQ1 2014 earnings before the market opens on Tuesday, April 15th.